Therapeutic Effect of Vitamin C Supplementation in Patients With Ovarian Aging
NCT ID: NCT06794060
Last Updated: 2025-06-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
354 participants
INTERVENTIONAL
2025-07-02
2027-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Does Vitamin C supplementation improve the ovarian reserve prediction score?
* What medical problems do participants have when taking Vitamin C supplementation?
Researchers will compare Vitamin C to a placebo (a look-alike substance that contains no drug) to see if drug Vitamin C works to improve ovarian reserve in women with ovarian aging. Participants will:
* Take Vitamin C or a placebo every day for 12 months
* Visit the clinic once every 4 weeks for follow-up and drug distribution.
* Return the Vitamin C box at each visit.
* Report any adverse effects of treatment to the doctor.
* Fill out a questionnaire at each visit.
* After 6 months and 12 months of intervention, take blood test and ultrasonic examination.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of VitC on IVF Outcome of DOR Patients
NCT06794047
Effects of Resveratrol Supplementation on Oocyte Quality
NCT06235294
A Clinical Study of Baozhu Keli in the Treatment of Ovarian Aging
NCT06256783
Can Antioxidants Affect Pregnancy Rate in Patients With Expected Low Number of Egg Retrieval in IVF Cycles?
NCT03085030
Effect of NMN (Nicotinamide Mononucleotide) on Diminished Ovarian Reserve (Including Premature Ovarian Insufficiency)
NCT05485610
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
After the follow-up, independent personnel who maintained the blind data provided group information to the data analysts. The synthetic vitamin C, natural vitamin C and control groups were still represented as A, B and C, concealing the specific identities of the ABC groups from the data analysts. After the data comparison between the two groups the unblinding of the AB groups was conducted.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Synthetic vitamin C
Participants will take the synthetic vitamin C twice a day, 500mg per time.
Vitamin C (Ascorbic Acid)
Participants swallow synthetic vitamin C tablets 500mg with water, twice a day.
Natural vitamin C
Participants will take the natural vitamin C twice a day, 500mg per time.
Vitamin C (Ascorbic Acid)
Participants swallow naturral vitamin C tablets 500mg with water, twice a day.
Placebo
Participants will take tablets with the same texture, flavor, and appearance as the experimental group twice a day, 500mg per time.
Placebo
Participants swallow tablets with the same texture, flavor, and appearance as the experimental group 500mg with water, twice a day.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vitamin C (Ascorbic Acid)
Participants swallow synthetic vitamin C tablets 500mg with water, twice a day.
Vitamin C (Ascorbic Acid)
Participants swallow naturral vitamin C tablets 500mg with water, twice a day.
Placebo
Participants swallow tablets with the same texture, flavor, and appearance as the experimental group 500mg with water, twice a day.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 10U/Lā¤ FSH\<25 U/L in two tests more than 4weeks aprt.
* AMH \< 1.1 ng/mL.
* Bilateral ovarian AFC \<7.
* Signed informed consent and can participate in regular follow-ups.
Exclusion Criteria
* Ovarian aging caused by ovarian surgery or chemotherapy.
* Patients with severe endocrine system diseases (diabetes, thyroid disease), digestive system diseases (affecting VC absorption), cardiovascular system diseases, renal insufficiency (abnormal urine, imaging diagnosis, blood, pathological analysis confirms that kidney damage does exist, or glomerular filtration rate GFR \<60mL/min), nervous system diseases such as dementia and epilepsy; patients with infectious diseases such as HIV, hepatitis, tuberculosis; patients with severe autoimmune diseases.
* Continuous alcohol or drug abuse (to avoid adverse reactions caused by drinking).
* Allergic to vitamin C or any component of the preparation.
* Patients who have already started large-dose (greater than 500mg/day) vitamin C supplementation.
* Unwilling to or stop taking supplements not provided by this project.
* Those who have participated in other ovarian aging clinical intervention projects.
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking University Third Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jie Qiao
Professor
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M2024647
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.